New dermatological agents for the treatment of psoriasis

Journal of Medicinal Chemistry

Volumn 44, Issue 3, 2001, Pages 281-297

  Thacher, S M ^a   Vasudevan, J ^a   Tsang, K Y ^a   Nagpal, S ^a   Chandraratna, R A S ^a  

^a ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 PROPYL 3 [3 [2 ETHYL 4 (4 FLUOROPHENYL) 5 HYDROXYPHENOXY]PROPOXY]PHENOXY]BENZOIC ACID; 20 EPI 22 ETHOXY 24A,26A,27A TRIHOMO 9,10 SECOCHOLESTA 5,7,10(19) TRIEN 23 YNE 1ALPHA,3BETA,25 TRIOL; 20 EPICALCITRIOL; 22 OXACALCITRIOL; 7 [3 [2 (CYCLOPROPYLMETHYL) 3 METHOXY 4 (4 THIAZOLYL)PHENOXY]PROPOXY] 3,4 DIHYDRO 8 PROPYL 2H 1 BENZOPYRAN 2 CARBOXYLIC ACID; ASCOMYCIN; CALCIPOTRIOL; CALCITRIOL; CYCLOSPORIN A; DERMATOLOGICAL AGENT; FUMARIC ACID DERIVATIVE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; LEXACALCITOL; LIAROZOLE; MC 1275; MERIMEPODIB; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN KINASE C INHIBITOR; RETINOID; STAUROSPORINE; TACALCITOL; TACROLIMUS; TAZAROTENE; TERIFLUNOMIDE; TRIMETREXATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZK 158252;

DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; PATHOPHYSIOLOGY; PSORIASIS; REVIEW; STRUCTURE ACTIVITY RELATION; ULTRAVIOLET RADIATION;

ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS; CHOLECALCIFEROL; CLINICAL TRIALS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIGANDS; METHOTREXATE; PSORIASIS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; VITAMIN A;

EID: 0035254533     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0000214     Document Type: Review

References (190)

1. Treatment of psoriasis
2. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
3. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: A new therapeutic approach
4. Fibronectin and α5 intergrin regulate keratinocyte cell cycling. A mechanism for increased fibronectin potentiation of T cell lymphokine-driven keratinocyte hyperproliferation in psoriasis
5. Dermal injection of immunocytes induces psoriasis
6. Immunosuppressive properties of methotrexate: Apoptosis and clonal deletion of activated peripheral T cells
7. Sunlight-induced basal cell carcinoma tumor cells and ultraviolet-B-irradiated psoriatic plaques express Fas ligand (CD95L)
8. 312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions
9. Cell kinetics in psoriasis: The use of animal and human skin models
10. Response of psoriasis to a new topical retinoid, AGN 190168
11. Monoclonal antibody analysis of keratin expression in epidermal diseases: A 48- and 56-Kdalton keratin as molecular markers for hyperproliferative keratinocytes
12. The small proline-rich proteins consititute a multigene family of differentially regulated cornifled cell envelope precursor proteins
13. Changes in keratinocyte maturation during wound healing
14. Cellular actions of etretinate in psoriasis: Enhanced epidermal differentiation and reduced cell-mediated inflammation are unexpected outcomes
15. Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype
16. Heparin-binding ligands mediate autocrine epidermal growth factor receptor activation in skin organ culture
17. Interleukin 1 binds to specific receptors on human keratinocytes and induces granulocyte macrophage-colony stimulating factor mRNA and protein
18. Production of interleukin-8 by human dermal fibroblasts and keratinocytes in response to interleukin-1 or tumor necrosis factor
19. GRO-α mRNA is selectively overexpressed in psoriatic epidermis and is reduced by cyclosporin A in vivo, but not in cultured keratinocytes
20. Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: Modulation by recombinant gamma interferon and tumor necrosis factor
21. GM-CSF activates regenerative epidermal growth and stimulates keratinocyte proliferation in human skin in vivo
22. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells
23. Elevated numbers of proliferating mononuclear cells in the peripheral blood of psoriatic patients correlate with disease severity
24. Duration of remission of psoriasis therapies
25. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response
26. Interleukin 10 treatment of psoriasis: Clinical results of a phase 2 trial
27. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions
28. Effects of the immunosuppressive drugs CsA and FK506 on intracellular signaling and gene regulation
29. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis
30. The genetics of psoriasis
31. Animal models of psoriasis
32. A perspective of psoriasis as an aberration in skin modified to expression by the inflammatory/repair system
33. Suprabasal integrin expression in the epidermis of transgenic mice results in developmental defects and a phenotype resembling psoriasis
34. Treatment of Psoriasis
35. Trimethylpsoralen bath PUVA is a remittive treatment for psoriasis vulgaris. Evidence that epidermal immunocytes are direct therapeutic targets
36. Treatment of psoriasis with fumaric acid esters: Scientific background and guidelines for therapeutic use
37. Restoration of collagen formation in photodamaged skin by tretinoin (retinoic acid)
38. Optimising the use of tazarotene in clinical practice: Consensus statement from the European advisory panel for tazarotene (Zorac TM)
39. New twists in gene regulation by glucocorticoid receptor: Is DNA binding dispensable?
40. Vitamin D
41. 3, receptors in human skin biopsies
42. 3
43. 3, on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions
44. 22-Oxa calcitriol is a less potent regulator of keratinocyte proliferation and differentiation due to decreased cellular uptake and enhanced catabolism
45. 3
46. 3, for psoriasis: Report of five cases
47. Long-term use of topical calcipotriol in chronic plaque psoriasis
48. Structure-function relationships in the Vitamin D endocrine system
49. Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial
50. Topical maxacalcitol for the treatment of psoriasis vulgaris: A placebo-controlled, double-blind, dose-finding study with active comparator
51. 3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocyes
52. Simultaneous assessment of inflammation and epidermal proliferation in psoriatic plaques during long-term treatment with the vitamin D3 analogue MC903: Modulations and interrelations
53. 3: A cell biological study
54. Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions
55. 3 in human peripheral blood mononuclear cells: Presence in monocytes and induction in T lymphocytes following activation
56. 3: A novel immunoregulatory hormone
57. Cloning and expression of full-length cDNA encoding human vitamin D receptor
58. Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors
59. 3-response element in the 5′-flanking region of the rat calbindin D-9k gene
60. 3 leads to the induced differentiation of the myelomonocytic cell line U937
61. Inhibitory function of p21Cip1/WAF1 in differentiation of primary mouse keratinocytes independent of cell cycle control
62. 3 receptor. Implications for allosteric influences on nuclear receptor structure and function by a DNA element
63. Calcipotriol: A new drug for topical psoriasis treatment
64. The antiproliferative and differentiation-inducing effects of Vitamin D analogues are not determined by the binding to the Vitamin D receptor alone
65. 3 with high activity for inducing epidermal differentiation but decreased hypercalcemic activity
66. Tacalcitol ointment in the treatment of psoriasis vulgaris: A multicentre, placebo-controlled, double-blind study on efficacy and safety
67. 3 analogue KH1060
68. Differential interaction of 1alpha,25-dihydroxyvitamin D3 analogues and their 20-epi homologues with the vitamin D receptor
69. 3
70. The vitamin D analogue KH1060, is rapidly degraded both in vivo and in vitro via several pathways: Principal metabolites generated retain significant biological activity
71. 1Alpha,25-dihydroxy-3-epi-vitamin D3, a natural metabolite of 1alpha,25-dihydroxyvitamin D3, is a potent suppressor of parathyroid hormone secretion
72. 3 in basal-lateral memranes of chick intestinal epithelium and relationship to transcaltachia
73. Nongenomic rapid effects of Vitamin D
74. A decade of molecular biology of retinoic acid receptors
75. Therapeutic applications for ligands of retinoid receptors
76. The Retinoid receptors
77. RARs and RXRs: Evidence for two autonomous transactivation functions (AF-1 and AF-2) and heterodimerization in vivo
78. Tazaratone-induced gene 1 (TIG1), a novel retinoic acid receptor-responsive gene in skin
79. Receptor specificity of retinoid-induced hyperplasia. Effect of RXR-selective agonists and correlation with topical irritation
80. Oral retinoids - Efficacy and toxicity in psoriasis
81. Effects of gemfibrozil (Lopid) on hyperlipidemia in acitretin-treated patients. Results of a double-blind crossover study
82. Osteoporosis is a toxic effect of long-term etretinate therapy
83. Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis
84. Negative regulation of the rat stromelysin gene promoter by retinoic acid is mediated by an AP1 binding site
85. Separation of transactivation and AP1 antagonism functions of retinoic acid receptor α
86. Retinoid antagonism of NF-IL6: Insight into the mechanism of antiproliferative effects of retinoids in Kaposi's sarcoma
87. Retinoic acid receptor-nuclear factor-interleukin 6 antagonism. A novel mechanism of retinoid-dependent inhibition of a keratinocyte hyperproliferative differentiation marker
88. Retinoids as anti-cancer agents
89. Tazaratene-first of a new generation of receptor-selective retinoids
90. Negative regulation of two hyperproliferative keratinocyte differentiation markers by a retinoic acid receptor-specific retinoid: Insight into the mechanism of retinoid action in psoriasis
91. Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin
92. Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene
93. Effect of topical tazarotene in the treatment of congenital ichthyoses
94. Efficacy, tolerability, and safety of calcipotriol ointment in disorders of keratinization. Results of a randomized, double-blind, vehicle-controlled, right/left comparative study
95. Control of growth regulatory and differentiation-specific genes in human epidermal keratinocytes by interferon γ
96. Fas ligand: A sensor for DNA damage critical in skin cancer etiology
97. Use of methotrexate in psoriasis
98. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5′-nucleotidase-mediated conversion of adenine nucleotides
99. Folate antifolate pharmacology
100. Targets of immunophilin-immunosuppresant complexes are distinct highly conserved regions of calcineurin A
101. The mechanism of action of cyclosporin A and FK506
102. Ascomycins in dermatology
103. Cyclosporine A for psoriasis
104. Cyclosporine in psoriasis: A multicenter dose-finding study in severe plaque psoriasis
105. The enigma of cyclosporin A treatment for psoriasis: Systemic efficacy versus topical nonresponsiveness
106. Intralesional cyclosporine for psoriasis. Relationship of dose, tissue levels, and efficacy
107. FK-506, a novel immunosuppressant isolated from a streptomyces II: Immunosuppressive effect of FK-506 in vitro
108. Tacrolimus (FK 506) - A new therapeutic agent for severe recalcitrant psoriasis
109. Immunosuppressive macrolides of the type FK 506: A novel class of topical agents for treatment of skin diseases?
110. Tacrolimus ointment improves psoriasis in a microplaque assay
111. Tacrolimus ointment does not affect collagen synthesis: Results of a single-center randomized trial
112. FR-900520 and FR-900523, novel immunosuppressants isolated from a Streptomyces. II: Fermentation, isolation and physicochemical and biological characteristics
113. Identity of immunosuppressant FR-900520 with ascomycin
114. The chemistry of ascomycin: Structure determination and synthesis of pyrazole analogues
115. Discovery of ascomycin analogues with potent topical but weak systemic activity for treatment of inflammatory skin diseases
116. Clearing of psoriasis by a novel immunosuppressive macrolide
117. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion
118. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis
119. Localization of endothelial proliferation and microvascular expansion in active plaque psoriasis
120. cDNA cloning of human retinoic acid-metabolizing enzyme (hP450RAI) identifies a novel family of cytochromes P450
121. Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo
122. The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin
123. Effects of systemic treatment with liarozole on cutaneous inflammation, epidermal proliferation and differentiation in extensive plaque psoriasis
124. R115866 inhibits all-trans-retinoic acid metabolism and exerts retinoidal effects in rodents
125. Administration of DAB389IL-2 to patients with recalcitrant psoriasis: A double-blind, phase II multicenter trial
126. Treatment of recalcitrant plaque psoriasis with a humanized nondepleting antibody to CD4
127. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis
128. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid
129. Mycephenolic acid in psoriasis
130. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil
131. The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors
132. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate
133. Future developments of anitpsoriatic therapy
134. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide
135. The identification of hydroxy fatty acids in psoriatic skin
136. Investigation on a novel and specific leukotriene B4 receptor antagonist in the treatment of stable plaque psoriasis
137. The regulation of CD11b integrin levels on human blood leukocytes and leukotriene B4-stimulated skin by a specific leukotriene B4 receptor antagonist (LY293111)
138. 4 receptor antagonist ZK 158252
139. 4 antagonist of the growth of psoriatic papules
140. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease
141. Differential expression of protein kinase C isoenzymes in normal and psoriatic adult human skin: Reduced expression of protein kinase C-beta II in psoriasis
142. Evidence for an altered protein kinase C (PKC) signaling pathway in psoriasis
143. 2+-dependent protein kinase
144. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor
145. Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976
146. Indolocarbazole nitrogens linked by three-atom bridges: A potent new class of PKC inhibitors
147. SCH 47112, a novel staurosporine derivative, inhibits 12-O-tetradecanoylphorbol-13-acetate-induced inflammation and epidermal hyperplasia in hairless mouse skin
148. Overexpression of transforming growth factor alpha in psoriatic epidermis
149. Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases
150. Tyrphostins suppress the growth of psoriatic keratinocytes
151. Tyrosine kinase inhibition: An approach to drug development
152. The inhibition of EGF-dependent proliferation of keratinocytes by tyrphostin tyrosine kinase blockers
153. Protein tyrosine kinase inhibitors in cancer treatment
154. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of tyrosine kinase activity of the epidermal growth factor receptor
155. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor
156. Protein tyrosine kinase inhibitors as novel therapeutic agents
157. The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases
158. Synthesis and pharmacology of conformationally restricted raloxifene analogues: Highly potent selective estrogen receptor modulators
159. Estrogen and raloxifene stimulate transforming growth factor-β3 gene expression in rat bone: A potential mechanism for estrogen- or raloxifene-mediated bone maintenance
160. The molecular pharmacology of SERMs
161. Identification and functional separation of retinoic acid receptor neutral antagonists and inverse agonists
162. Cell type and gene-specific activity of the retinoid inverse agonist AGN 193109: Divergent effects from agonist at retinoic acid receptor-γ in human keratinocytes
163. Synthesis and biological activity of high affinty RAR antagonists
164. The coregulator exchange intranscriptional functions of nuclear receptors
165. Recruitment of nuclear receptor corepressor and coactivator to the retinoic acid receptor by retinoid ligands. Influence of DNA heterodimer interactions
166. Peptide antagonists of the human estrogen receptor
167. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo
168. Dissociated glucocorticoids with antiinflammatory potential repress interleukin-6 gene expression by a nuclear factor-κB-dependent mechanism
169. 3 analogue toward Vitamin D receptor function
170. Role of retinoic acid receptor gamma in the Rhino mouse and rabbit irritation models of retinoic acitivity
171. Identification of a retinoic acid receptor α specific agonist
172. Retinoic acid receptor beta, gamma-selective ligands: Synthesis and biological activity of 6-substituted 2-naphthoic acid retinoids
173. Lack of involvement of retinoic acid receptor α in retinoid-induced skin irritation in hairless mice
174. E3, a hematopoietic-specific transcript directly regulated by the retinoic acid receptor alpha
175. Identification of highly potent retinoic acid receptor α-selective antagonists
176. Orphan nuclear receptors: From gene to function
177. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response
178. Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene
179. Treatment of psoriasis with troglitazone therapy
180. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: Ligands for peroxisome proliferater-activated receptor-gamma inhibit keratinocyte proliferation
181. Requirement for RORγ in thymocyte survival and lymphoid organ development
182. Animal models of psoriasis - What can we learn from them?
183. Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis
184. Inflammatory skin diseases, T cells, and immune surveillance
185. Combinatorial thinking in chemistry and biology
186. Interleukin-2 signaling and inherited immunodeficiency